Current status of overall assessment and systematic treatment of gastric cancer in the elderly

doi:10.16138/j.1673-6087.2024.03.08

Abstract

Abstract:

The incidence and mortality rate of gastric cancer are among the top five malignant tumors, and the majority is elderly people. However, clinical research and related guidelines for elderly patients are not insufficient. This article summarizes the recent research progress of the overall evaluation, surgical treatment, perioperative treatment, chemotherapy and targeted therapy of gastric cancer in the elderly, to provide some reference for the clinical practice.

Key words: Gastric cancer in the elderly, Overall evaluation, Systematic treatment, Genome

CLC Number:

R581.1

XU Shan, XU Chao. Current status of overall assessment and systematic treatment of gastric cancer in the elderly[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(03): 193-196.

References 28

[1]	Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer[J]. Lancet, 2020, 396(10251):635-648. doi: S0140-6736(20)31288-5 pmid: 32861308
[2]	Pak LM, Wang J. The appropriate treatment for elderly gastric cancer patients[J]. Art Surg, 2017, 1:4.
[3]	Lee H, Lee E, Jang IY. Frailty and comprehensive geriatric assessment[J]. J Korean Med Sci, 2020, 35(3):e16.
[4]	Hamamoto Y, Piao Y, Makiyama A. Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites[J]. Gastric Cancer, 2020, 23(3):363-372. doi: 10.1007/s10120-020-01067-3 pmid: 32236760
[5]	Mittal A, Rangaraju RR, Agarwal A, et al. Estimating the risk of chemotherapy toxicity in Indian geriatric patient population and utility of chemotherapy risk assessment scale for high age patients (CRASH) score[J]. South Asian J Cancer, 2021, 10(3):161-166. doi: 10.1055/s-0041-1729447 pmid: 34938678
[6]	Pang A, Jiali L, Ng A, et al. Use of the cancer and aging research group predictive model for chemotherapy-related toxic effects in a multiethnic, older adult Asian population[J]. JAMA Netw Open, 2022, 5(10):e2237196.
[7]	Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies[J]. Pharmacol Res Perspect, 2019, 7(6):e00535.
[8]	Loizides S, Papamichael D. Considerations and challenges in the management of the older patients with gastric cancer[J]. Cancers (Basel), 2022, 14(6):1587.
[9]	Zhang Z, Huang J, Li Y, et al. Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer[J]. Aging (Albany NY), 2024, 16(1):948-963.
[10]	Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(3):329-359.
[11]	Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition)[J]. Gastric Cancer, 2021, 24(1):1-21.
[12]	Xu WS, Zhang HY, Jin S, et al. Efficacy and safety of endoscopic submucosal dissection for early gastric cancer and precancerous lesions in elderly patients[J]. World J Gastrointest Surg, 2024, 16(2):511-517.
[13]	Ciesielski M, Kruszewski WJ, Szajewski M, et al. Extremely high mortality rate after a successful gastrectomy for cancer in older adults[J]. J Gastric Cancer, 2019, 19(2):202-211. doi: 10.5230/jgc.2019.19.e16 pmid: 31245165
[14]	Yazici H, Eren A, Uprak TK, et al. Gastric cancer surgery during the pandemic: what it costs?[J]. J Gastrointest Cancer, 2022, 53(4):848-853.
[15]	Jeong SA, Yook JH, Yoo MW, et al. Analysis of risk factors affecting long-term survival in elderly patients with advanced gastric cancer[J]. Aging Clin Exp Res, 2023, 35(10):2211-2218.
[16]	Petrillo A, Pompella L, Tirino G, et al. Perioperative treatment in resectable gastric cancer: current perspectives and future directions[J]. Cancers (Basel), 2019, 11(3):399.
[17]	Charruf AZ, Ramos MFKP, Pereira MA, et al. Impact of neoadjuvant chemotherapy on surgical and pathological results of gastric cancer patients[J]. J Surg Oncol, 2020, 121(5):833-839. doi: 10.1002/jso.25839 pmid: 31943232
[18]	Wu F, Hong J, Du N, et al. Long-term outcomes of neoadjuvant chemotherapy in locally advanced gastric cancer/esophagogastric junction cancer[J]. Anticancer Agents Med Chem, 2022, 22(1):143-151.
[19]	Joharatnam-Hogan N, Shiu KK, Khan K. Challenges in the treatment of gastric cancer in the older patient[J]. Cancer Treat Rev, 2020, 85:101980.
[20]	Forouhari A, Moghaddas A, Darakhshandeh A. Outcome evaluation of ECF, DCF, FOLFOX, and FLOT chemotherapy regimens as perioperative treatment in elderly patients with resectable gastric cancer[J]. J Res Med Sci, 2023, 28:79. doi: 10.4103/jrms.jrms_417_22 pmid: 38292337
[21]	Ota M, Saeki H, Uehara H, et al. Phase Ⅱ clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients[J]. Int J Clin Oncol, 2023, 28(9):1166-1175.
[22]	Sugimoto A, Nishida T, Osugi N, et al. Prediction of survival benefit when deciding between chemotherapy and best supportive therapy in elderly patients with advanced gastric cancer[J]. Mol Clin Oncol, 2019, 10(1):83-91. doi: 10.3892/mco.2018.1772 pmid: 30655981
[23]	Jiang Z, Zhou A, Sun Y, et al. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy[J]. BMC Cancer, 2022, 22(1):253.
[24]	Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4)[J]. Lancet, 2019, 393(10184):1948-1957.
[25]	Nie RC, Chen GM, Wang Y, et al. Efficacy of anti-PD-1/PD-L1 monotherapy or combinational therapy in patients aged 75 years or older[J]. Front Oncol, 2021, 11:538174.
[26]	Ninomiya K, Oze I, Kato Y, et al. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis[J]. Acta Oncol, 2020, 59(3):249-256. doi: 10.1080/0284186X.2019.1695062 pmid: 31782328
[27]	Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649)[J]. Lancet, 2021, 398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2 pmid: 34102137
[28]	Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590)[J]. Lancet, 2021, 398(10302):759-771.